Approval of New Version of Prevnar Lifts Pfizer - WSJ.com

[Guest guest]

aren't you glad t hey got a 'lift'?

Sheri

A new version of the Prevnar childhood vaccine won regulators'

approval Wednesday, giving maker

Pfizer Inc. a quick and important lift from its takeover of rival

Wyeth last year.

The Food and Drug Administration approved Prevnar 13 for treatment of

infants and toddlers with " pneumococcal " illnesses, such as ear

infections, pneumonia and meningitis. Now, the Centers for Disease

Control and Prevention must decide whether to recommend the vaccine's

routine use. A panel of experts advising the agency is scheduled to

debate the subject at meetings starting later Wednesday.

Pfizer has been counting on the new vaccine, and the approval marks an

important early success for the Wyeth deal. After struggling to find new

blockbusters, Pfizer bought Wyeth for $68 billion to help offset sales it

will lose when cholesterol drug Lipitor loses patent protection late next

year. The older Prevnar 7 had been a top performer for Wyeth, generating

$2.7 billion in sales in 2008, according to the most recent results

available.

Analysts generally expect the new Prevnar, for which Pfizer plans to

charge a premium, to be a strong performer. Credit Suisse analyst

Arnold estimates that Prevnar 13 will have $5.9 billion in

sales in 2015, more than any other single Pfizer product. " We think

it is the most important value driver for the future of Pfizer, " she

said.

http://online.wsj.com/article/SB10001424052748704240004575085423525747254.html?mod=rss_whats_news_us_business

Sheri Nakken, R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://vaccinationdangers.wordpress.com/ Homeopathy

http://homeopathycures.wordpress.com

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start February 24 & 25

[Guest guest]

aren't you glad t hey got a 'lift'?

Sheri

A new version of the Prevnar childhood vaccine won regulators'

approval Wednesday, giving maker

Pfizer Inc. a quick and important lift from its takeover of rival

Wyeth last year.

The Food and Drug Administration approved Prevnar 13 for treatment of

infants and toddlers with " pneumococcal " illnesses, such as ear

infections, pneumonia and meningitis. Now, the Centers for Disease

Control and Prevention must decide whether to recommend the vaccine's

routine use. A panel of experts advising the agency is scheduled to

debate the subject at meetings starting later Wednesday.

Pfizer has been counting on the new vaccine, and the approval marks an

important early success for the Wyeth deal. After struggling to find new

blockbusters, Pfizer bought Wyeth for $68 billion to help offset sales it

will lose when cholesterol drug Lipitor loses patent protection late next

year. The older Prevnar 7 had been a top performer for Wyeth, generating

$2.7 billion in sales in 2008, according to the most recent results

available.

Analysts generally expect the new Prevnar, for which Pfizer plans to

charge a premium, to be a strong performer. Credit Suisse analyst

Arnold estimates that Prevnar 13 will have $5.9 billion in

sales in 2015, more than any other single Pfizer product. " We think

it is the most important value driver for the future of Pfizer, " she

said.

http://online.wsj.com/article/SB10001424052748704240004575085423525747254.html?mod=rss_whats_news_us_business

Sheri Nakken, R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://vaccinationdangers.wordpress.com/ Homeopathy

http://homeopathycures.wordpress.com

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start February 24 & 25